Business & Tech

La Jolla Firm Resubmits Anti-Obesity Drug Application to FDA

Orexigen Therapeutics Inc. expects the FDA review process for its drug, Contrave, to take approximately 6 months.

There may be another anti-obesity drug on the market soon. La Jolla-based Orexigen Therapeutics Inc. resubmitted its application for its drug, Contrave, to the Food and Drug Administration.

The application process will likely take up to 6 months, according to the San Diego Business Journal

The business publication reported this is the second time Orexigen has applied for regulatory approval for Contrave. It said the company was refused in 2001 due to concerns of possible cardiovascular risk. Orexigen has conducted additional clinical trials since then with positive interim result, the SDBJ reported.

Interested in local real estate?Subscribe to Patch's new newsletter to be the first to know about open houses, new listings and more.


Get more local news delivered straight to your inbox. Sign up for free Patch newsletters and alerts.

We’ve removed the ability to reply as we work to make improvements. Learn more here